The FDA has notified healthcare professionals that the Boxed Warning for the tumor necrosis factor-alpha (TNF-alpha) blocker class of drugs has been updated to include the risk of infection from ...

May 29, 2009 — The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, ...

The existing boxed warnings on all tumor necrosis factor-alpha inhibiting drugs will be updated to reflect risk for infection with the bacteria Legionella and Listeria, the FDA announced. These ...

Pfizer withheld data indicating that the tumor necrosis factor alpha blocker Enbrel may reduce the risk for Alzheimer's disease. Tumor necrosis factor alpha mediates an increase in oxidation, ...

WASHINGTON (Reuters) - U.S. health regulators ordered stronger warnings for prescription drugs to treat rheumatoid arthritis, Crohn's disease and other conditions on Thursday after dozens of patients ...

Tumor necrosis factor (TNF)–alpha inhibitors achieve better endoscopic healing than the newer biologic drugs vedolizumab (Entyvio) and ustekinumab (Stelara) in moderate to severe Crohn's disease, a ...

FDA is tacking new, stronger warnings on TNF-alpha blockers. The new label language highlights an increased risk of cancer in children and adolescents who take the blockbuster meds. These drugs ...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced Phase ...

A new tumor necrosis factor alpha (TNF-α) blocker with a unique once-monthly dosing schedule has been approved, but despite its advantages, few believe it will shake up the market. Simponi (golimumab) ...

The push for new anti-inflammatory drugs has pharmaceutical companies flocking to a previously abandoned therapy. Heidi Ledford reports on the resurrection of interleukin-1 blockers. In 1977, ...